What does OXYCURE do?

OXYCURE is a healthcare practice in Fernelmont. Public Limited, started on 28 May 1998, 1 establishment.

What is the address of OXYCURE?

The registered office of OXYCURE is located at Rue Léopold Genicot, ZI, Nov. 9, 5380 Fernelmont.

Is OXYCURE still active?

Yes. According to the CBE (30 October 2026) OXYCURE is active, legal situation “Normale toestand”, started on 28 May 1998.

Is OXYCURE registered on Peppol?

Yes, OXYCURE is registered on the Peppol network with ID 0208:0463450459.

What is the enterprise number of OXYCURE?

The enterprise number of OXYCURE is BE0463450459.

When was OXYCURE founded?

OXYCURE was founded on 28 May 1998.

Who are the directors of OXYCURE?

According to the 2025 annual accounts, the directors of OXYCURE are: FRANCIS THOMAS, CHANTAL HARDY.

Is OXYCURE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 May 1998; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did OXYCURE make in 2025?

OXYCURE posted a profit after taxes of € 17,778 in financial year 2025.

What is the revenue of OXYCURE?

In its most recent annual accounts (2025), OXYCURE reported revenue of € 13,834,574.

How much does an employee at OXYCURE earn?

The average wage cost per full-time employee at OXYCURE was € 72,600 in 2025: staff costs of € 4.4 million for 60.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does OXYCURE have?

According to the 2025 annual accounts, OXYCURE has 60.1 full-time equivalents (FTE).

Does OXYCURE have a website?

Yes, OXYCURE has a website at oxycure.be.

OXYCURE (Public Limited) - Fernelmont - BE0463450459

Dossier OXYCURE, printed on 30 October 2026 from databakkes.be/en/0463450459/oxycure. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 67.1 to 60.1.
Figures corrected NBB

Corrected annual account filed for 2022.

Financials

Financial year 2025

OXYCURE from Fernelmont, company number BE0463450459, closed financial year 2025 with a result of € 17,778 after tax. For that financial year OXYCURE recorded revenue of € 13.8 million and equity of € 2.4 million. Compared with financial year 2024, the result moved from € -258,232 to € 17,778. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on January 29, 2026.

What it is worth Growing

€ 2.4 million

▲ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 17,778

▲ still € 258,232 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1 million

▼ 2% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.4 million.

People and assets in 2025

Full-time equivalents

60.1

▼ 1.8 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 6.2 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 4.4 million

▲ 1% vs 2024

€ 72,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 814,914

▼ 1% vs 2024

Of which on lease € 686,141.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 6.7 million

▼ 16% vs 2024

€ 1.4 million is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 955,243

▲ 27% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 51 days on average.

Taxes and wages

€ 872,478

▼ 1% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 12,464,236 Revenue 2022: € 12,464,236 First fiscal year in the series	€ 14,148,532 Revenue 2023: € 14,148,532 ▲ 14% vs 2022 (€ 12,464,236) Favourable step	€ 14,175,411 Revenue 2024: € 14,175,411 Unchanged (€ 14,148,532) Favourable step	€ 13,834,574 Revenue 2025: € 13,834,574 ▼ 2% vs 2024 (€ 14,175,411) Unfavourable step	▼ 2%
Gross margin	€ 6,074,174 Gross margin 2022: € 6,074,174 First fiscal year in the series	€ 7,083,081 Gross margin 2023: € 7,083,081 ▲ 17% vs 2022 (€ 6,074,174) Favourable step	-	-
Profit after taxes	€ -466,800 Profit after taxes 2022: € -466,800 First fiscal year in the series	€ -1,311,074 Profit after taxes 2023: € -1,311,074 ▼ € 844,274 vs 2022 (€ -466,800) Unfavourable step	€ -258,232 Profit after taxes 2024: € -258,232 ▲ € 1.1 million vs 2023 (€ -1,311,074) Favourable step	€ 17,778 Profit after taxes 2025: € 17,778 ▲ € 276,009 vs 2024 (€ -258,232) Favourable step	▲ € 276,009
Equity	€ 3,942,910 Equity 2022: € 3,942,910 First fiscal year in the series	€ 2,667,561 Equity 2023: € 2,667,561 ▼ 32% vs 2022 (€ 3,942,910) Unfavourable step	€ 2,406,808 Equity 2024: € 2,406,808 ▼ 10% vs 2023 (€ 2,667,561) Unfavourable step	€ 2,419,198 Equity 2025: € 2,419,198 ▲ 1% vs 2024 (€ 2,406,808) Favourable step	▲ 1%
Total debts	€ 10,585,354 Total debts 2022: € 10,585,354 First fiscal year in the series	€ 9,466,675 Total debts 2023: € 9,466,675 ▼ 11% vs 2022 (€ 10,585,354) Favourable step	€ 9,715,562 Total debts 2024: € 9,715,562 ▲ 3% vs 2023 (€ 9,466,675) Unfavourable step	€ 8,590,347 Total debts 2025: € 8,590,347 ▼ 12% vs 2024 (€ 9,715,562) Favourable step	▼ 12%
Cash	€ 853,785 Cash 2022: € 853,785 First fiscal year in the series	€ 523,199 Cash 2023: € 523,199 ▼ 39% vs 2022 (€ 853,785) Unfavourable step	€ 1,060,837 Cash 2024: € 1,060,837 ▲ 103% vs 2023 (€ 523,199) Favourable step	€ 1,041,753 Cash 2025: € 1,041,753 ▼ 2% vs 2024 (€ 1,060,837) Unfavourable step	▼ 2%
Land & buildings	€ 3,798,893 Land & buildings 2022: € 3,798,893 First fiscal year in the series	€ 3,196,895 Land & buildings 2023: € 3,196,895 ▼ 16% vs 2022 (€ 3,798,893) Unchanged	€ 2,822,216 Land & buildings 2024: € 2,822,216 ▼ 12% vs 2023 (€ 3,196,895) Unchanged	€ 2,519,203 Land & buildings 2025: € 2,519,203 ▼ 11% vs 2024 (€ 2,822,216) Unchanged	▼ 11%
Retained profit	€ 2,945,110 Retained profit 2022: € 2,945,110 First fiscal year in the series	€ 1,634,036 Retained profit 2023: € 1,634,036 ▼ 45% vs 2022 (€ 2,945,110) Unfavourable step	€ 1,375,805 Retained profit 2024: € 1,375,805 ▼ 16% vs 2023 (€ 1,634,036) Unfavourable step	€ 1,393,582 Retained profit 2025: € 1,393,582 ▲ 1% vs 2024 (€ 1,375,805) Favourable step	▲ 1%
Bank debt	€ 7,862,132 Bank debt 2022: € 7,862,132 First fiscal year in the series	€ 6,593,354 Bank debt 2023: € 6,593,354 ▼ 16% vs 2022 (€ 7,862,132) Favourable step	€ 7,998,056 Bank debt 2024: € 7,998,056 ▲ 21% vs 2023 (€ 6,593,354) Unfavourable step	€ 6,714,748 Bank debt 2025: € 6,714,748 ▼ 16% vs 2024 (€ 7,998,056) Favourable step	▼ 16%
Balance sheet total	€ 14,712,886 Balance sheet total 2022: € 14,712,886 First fiscal year in the series	€ 12,333,267 Balance sheet total 2023: € 12,333,267 ▼ 16% vs 2022 (€ 14,712,886) Unchanged	€ 12,332,932 Balance sheet total 2024: € 12,332,932 Unchanged (€ 12,333,267) Unchanged	€ 11,215,786 Balance sheet total 2025: € 11,215,786 ▼ 9% vs 2024 (€ 12,332,932) Unchanged	▼ 9%
Employees (FTE)	51.4 Employees (FTE) 2022: 51.4 First fiscal year in the series	67.1 Employees (FTE) 2023: 67.1 ▲ 15.7 vs 2022 (51.4) Unchanged	61.9 Employees (FTE) 2024: 61.9 ▼ 5.2 vs 2023 (67.1) Unchanged	60.1 Employees (FTE) 2025: 60.1 ▼ 1.8 vs 2024 (61.9) Unchanged	▼ 1.8

Key figures of OXYCURE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to OXYCURE?

What happened at OXYCURE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 FRANCIS THOMAS stepped down as director. NBB
2029 CHANTAL HARDY stepped down as director. NBB
Jan 29, 2026 New annual accounts for financial year 2025: profit of € 17,778. Source: NBB ↗
2023 FRANCIS THOMAS became a director. NBB
2023 CHANTAL HARDY became a director. NBB
Jul 3, 2002 New establishment in Fernelmont. KBO
May 28, 1998 Start of the company according to the CBE. KBO

In short

From € 466,800 loss in 2022 to € 17,778 profit in 2025.

Paid € 110,490 in corporate taxes since 2022.

Best year ever: 2025, with € 17,778 profit.

On average € 105,600 of value added per employee in 2023.

Original PDFs at the National Bank ↗

Management

FRANCIS THOMAS 50%

CHANTAL HARDY 50%

OXYCURE

The shares are held by FRANCIS THOMAS (50%) and CHANTAL HARDY (50%).

Directors

According to the 2025 annual accounts

FRANCIS THOMAS

Director

since 2023 · until 2029

CHANTAL HARDY

Director

since 2023 · until 2029

Shareholders

FRANCIS THOMAS

50%

CHANTAL HARDY

50%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Léopold Genicot, ZI, Nov. 9

5380 Fernelmont

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

SOBEMAG

€ -5,329 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS oxycure.be

Canonical: https://www.oxycure.be/

Technologies

ApacheContact Form 7Font AwesomeGoogle FontsLightboxPHPVimeoWPMLWordPressWordfenceYouTube EmbedjQueryreCAPTCHA

Hosting & Email

Email provider

Self-hosted

Hosting

OVH, FR

DNS

Cloudflare DNS

Website info

HTTPS Ja

Languages FR, NL

Features

Security

✓ HTTPS

✓ SPF

✓ DMARC

Details

Company number

0463.450.459

VAT number

BE 0463.450.459

Registered office

Rue Léopold Genicot, ZI, Nov. 9, 5380 Fernelmont

Names & denominations

OXYCURE

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

28 May 1998

Peppol

Active · Active since 20 Nov 2020

Contact

oxycure.be

Activities · NACE

Activiteiten op het gebied van voeding

Detailhandel in farmaceutische producten

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Overige menselijke gezondheidszorg, n.e.g.

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Verhuur en lease van medisch en paramedisch materieel

Vervaardiging van geneesmiddelen

Groothandel in farmaceutische en medische artikelen

View on CBE Public ↗ Annual accounts (NBB) ↗

OXYCURE

Warning lights

Financials

What happened to OXYCURE?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Website

Technologies

Hosting & Email

Website info

Features

Security

Details

Frequently asked questions